Northwest Biotherapeutics (NWBO) EBIT (2010 - 2026)

Northwest Biotherapeutics' EBIT history runs 17 years deep, the most recent figure standing at -$10.9 million for Q1 2026.

• In Q1 2026, EBIT rose 37.03% year-over-year to -$10.9 million; the TTM figure through Mar 2026 stood at -$53.5 million (up 21.41% YoY), while the FY2025 annual figure was -$59.9 million, up 9.91% from the prior year.
• EBIT for Q1 2026 stood at -$10.9 million, up from -$13.5 million in the prior quarter.
• The five-year high for EBIT was -$10.9 million in Q1 2026, with the low at -$21.1 million in Q2 2022.
• The 5-year median for EBIT is -$14.8 million (2024), against an average of -$15.3 million.
• Peak annual rise in EBIT reached 37.22% in 2022, while the deepest fall reached 70.27% in 2022.
• Northwest Biotherapeutics' EBIT stood at -$18.2 million in 2022, then gained by 16.7% to -$15.1 million in 2023, then declined by 22.17% to -$18.5 million in 2024, then grew by 27.0% to -$13.5 million in 2025, then rose by 19.28% to -$10.9 million in 2026.
• Business Quant data shows NWBO's EBIT at -$10.9 million in Q1 2026, -$13.5 million in Q4 2025, and -$14.3 million in Q3 2025.